Guizhou Sanli Pharmaceutical Co Ltd (603439) - Total Liabilities
Based on the latest financial reports, Guizhou Sanli Pharmaceutical Co Ltd (603439) has total liabilities worth CN¥1.30 Billion CNY (≈ $190.23 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Guizhou Sanli Pharmaceutical Co Ltd cash conversion from operations to assess how effectively this company generates cash.
Guizhou Sanli Pharmaceutical Co Ltd - Total Liabilities Trend (2013–2024)
This chart illustrates how Guizhou Sanli Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Check Guizhou Sanli Pharmaceutical Co Ltd liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Guizhou Sanli Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Guizhou Sanli Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Compania de Transporte de Energia Electrica en Alta Tension Transener SA
BA:TRAN
|
Argentina | AR$280.60 Billion |
|
Afya Ltd
NASDAQ:AFYA
|
USA | $4.40 Billion |
|
BridgeBio Oncology Therapeutics, Inc.
NASDAQ:BBOT
|
USA | $37.28 Million |
|
Acast AB
ST:ACAST
|
Sweden | Skr942.78 Million |
|
Zhejiang Jasan Holding Group Co Ltd
SHG:603558
|
China | CN¥1.57 Billion |
|
Regal Partners Ltd
AU:RPL
|
Australia | AU$164.10 Million |
|
ECOVE Environment Corp
TWO:6803
|
Taiwan | NT$9.15 Billion |
|
Braskem SA Class A
NYSE:BAK
|
USA | $98.33 Billion |
Liability Composition Analysis (2013–2024)
This chart breaks down Guizhou Sanli Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Guizhou Sanli Pharmaceutical Co Ltd stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.45 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.88 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.46 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Guizhou Sanli Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Guizhou Sanli Pharmaceutical Co Ltd (2013–2024)
The table below shows the annual total liabilities of Guizhou Sanli Pharmaceutical Co Ltd from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥1.60 Billion ≈ $233.76 Million |
+31.90% |
| 2023-12-31 | CN¥1.21 Billion ≈ $177.22 Million |
+109.39% |
| 2022-12-31 | CN¥578.40 Million ≈ $84.64 Million |
+55.10% |
| 2021-12-31 | CN¥372.93 Million ≈ $54.57 Million |
+34.67% |
| 2020-12-31 | CN¥276.91 Million ≈ $40.52 Million |
+247.35% |
| 2019-12-31 | CN¥79.72 Million ≈ $11.67 Million |
+35.84% |
| 2018-12-31 | CN¥58.69 Million ≈ $8.59 Million |
-36.26% |
| 2017-12-31 | CN¥92.07 Million ≈ $13.47 Million |
+5.30% |
| 2016-12-31 | CN¥87.44 Million ≈ $12.79 Million |
+1.50% |
| 2015-12-31 | CN¥86.14 Million ≈ $12.60 Million |
-38.33% |
| 2014-12-31 | CN¥139.67 Million ≈ $20.44 Million |
+7.01% |
| 2013-12-31 | CN¥130.52 Million ≈ $19.10 Million |
-- |
About Guizhou Sanli Pharmaceutical Co Ltd
Guizhou Sanli Pharmaceutical Co.,Ltd, together with its subsidiaries, engages in the plantation, research, development, production, and sale of pharmaceutical products in China. The company offers respiratory system, tonic, gynecological, and orthopedic medications, as well as cardiovascular and cerebrovascular drugs, and other medicines. It also provides products in various dosage forms, includi… Read more